WO2002096468A3 - Methode zur diagnose und therapie des nierenzellkarzinoms - Google Patents

Methode zur diagnose und therapie des nierenzellkarzinoms Download PDF

Info

Publication number
WO2002096468A3
WO2002096468A3 PCT/DE2002/001999 DE0201999W WO02096468A3 WO 2002096468 A3 WO2002096468 A3 WO 2002096468A3 DE 0201999 W DE0201999 W DE 0201999W WO 02096468 A3 WO02096468 A3 WO 02096468A3
Authority
WO
WIPO (PCT)
Prior art keywords
renal cell
nbk
cell carcinoma
renal
diagnosis
Prior art date
Application number
PCT/DE2002/001999
Other languages
English (en)
French (fr)
Other versions
WO2002096468A2 (de
Inventor
Peter Daniel
Bernhard Gillissen
Original Assignee
Peter Daniel
Bernhard Gillissen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter Daniel, Bernhard Gillissen filed Critical Peter Daniel
Priority to US10/479,200 priority Critical patent/US20050053931A1/en
Priority to EP02748562A priority patent/EP1397163A2/de
Priority to AU2002319080A priority patent/AU2002319080A1/en
Publication of WO2002096468A2 publication Critical patent/WO2002096468A2/de
Publication of WO2002096468A3 publication Critical patent/WO2002096468A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Die Erfindung betrifft ein neues Mittel zur Diagnose und Therapie des Nierenzellkarzinoms, sowie anderer Nierentumore, beispielsweise des Wilms-Tumors, oder anderer, nicht der Niere entstammender Tumor. Anwendungsgebiete der Erfindung sind die Medizin und die pharmazeutische Industrie. Der Erfindung liegt die Aufgabe zu Grunde, die bei dem heutigen Bearbeitungsstand dringend erforderlichen neuen Behandlungsformen und auch neue diagnostische Mittel für Nierenzellkarzinome bereitzustellen. Überraschenderweise wurde gefunden, dass das NBK-Protein, das im normalen Nierengewebe hoch exprimiert ist, im Tumorgewebe überhaupt nicht oder nur sehr schwach exprimiert ist. Die Proteinexpression und der Verlust von NBK wurde bei 80 Nierenzellkarzinom-Proben mittels Immunhistochemie und Mutationsanalytik untersucht. Das erfindungsgemässe Verfahren zur Diagnose ist dadurch gekennzeichnet, dass die NBK-Protein-Konzentration bzw. die NBK-RNA-Menge im Geweb bestimmt wird. Das erfindungsgemässe Mittel zur Therapie des Nierenzellkarzinoms und anderer Nierentumore ist dadurch gekennzeichnet, dass es die NBK-Proteinkonzentration in Nierenzellen oder anderen Geweben erhöht und in diesen Zellen direkt den therapeutischen Effekt auslöst.
PCT/DE2002/001999 2001-05-31 2002-05-30 Methode zur diagnose und therapie des nierenzellkarzinoms WO2002096468A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/479,200 US20050053931A1 (en) 2001-05-31 2002-05-30 Method for the diagnosis and therapy of renal cell carcinoma
EP02748562A EP1397163A2 (de) 2001-05-31 2002-05-30 Methode zur diagnose und therapie des nierenzellkarzinoms
AU2002319080A AU2002319080A1 (en) 2001-05-31 2002-05-30 Method for the diagnosis and therapy of renal cell carcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10126473A DE10126473A1 (de) 2001-05-31 2001-05-31 Methode zur Diagnose und Therapie des Nierenzellkarzinoms
DE10126473.9 2001-05-31

Publications (2)

Publication Number Publication Date
WO2002096468A2 WO2002096468A2 (de) 2002-12-05
WO2002096468A3 true WO2002096468A3 (de) 2003-08-28

Family

ID=7686733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/001999 WO2002096468A2 (de) 2001-05-31 2002-05-30 Methode zur diagnose und therapie des nierenzellkarzinoms

Country Status (5)

Country Link
US (1) US20050053931A1 (de)
EP (1) EP1397163A2 (de)
AU (1) AU2002319080A1 (de)
DE (1) DE10126473A1 (de)
WO (1) WO2002096468A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20050071475A1 (en) * 2003-09-29 2005-03-31 Bennett Donald John Direct internet access in the global system for mobile communications
CA2680591A1 (en) * 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
JP2010540534A (ja) * 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
US20150218643A1 (en) * 2014-02-06 2015-08-06 Brittany N. Lasseigne Differential methylation level of cpg loci that are determinative of kidney cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015648A1 (en) * 1998-09-10 2000-03-23 The Uab Research Foundation Adenoviral vector encoding pro-apoptotic bax gene and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015648A1 (en) * 1998-09-10 2000-03-23 The Uab Research Foundation Adenoviral vector encoding pro-apoptotic bax gene and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DANIEL P T ET AL: "Reversal of classical, P-glycoprotein-mediated and atypical drug resistance by overexpression of the apoptosis promoters bak and bik/nbk-1.", ANNALS OF HEMATOLOGY, vol. 77, no. SUPPL. 2, 1998, Annual Congress of the German and Austrian Societies of Hematology and Oncology;Frankfurt, Germany; October 25-28, 1998, pages S38, XP009009185, ISSN: 0939-5555 *
DANIEL P T ET AL: "Reversal of classical, P-glycoprotein-mediated drug resistance by overexpression of the apoptosis promoters bak and bik/nbk-1.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 39, March 1998 (1998-03-01), 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, pages 599, XP001147805, ISSN: 0197-016X *
DANIEL PETER T ET AL: "Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice.", BLOOD, vol. 94, no. 3, 1 August 1999 (1999-08-01), pages 1100 - 1107, XP002238050, ISSN: 0006-4971 *
HAN JEONGHOON ET AL: "Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K.", MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 10, 1996, pages 5857 - 5864, XP002238051, ISSN: 0270-7306 *
IMAI E ET AL: "TOWARDS GENE THERAPY FOR RENAL DISEASES", NEPHROLOGIE, EDITIONS MEDECINE ET HYGIENE, GENEVA, CH, vol. 19, no. 7, 1998, pages 397 - 402, XP009007604, ISSN: 0250-4960 *
VERMA S ET AL: "Structural analysis of the human pro-apoptotic gene Bik: Chromosomal localization, genomic organization and localization of promoter sequences", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 254, no. 1-2, 22 August 2000 (2000-08-22), pages 157 - 162, XP004208791, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
DE10126473A1 (de) 2003-09-04
AU2002319080A1 (en) 2002-12-09
US20050053931A1 (en) 2005-03-10
EP1397163A2 (de) 2004-03-17
WO2002096468A2 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
Toncev et al. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood–brain barrier dysfunction
Leibowitz et al. Uncoupling p53 functions in radiation-induced intestinal damage via PUMA and p21
Sánchez et al. Identification of the major protein components in breast secretions from women with benign and malignant breast diseases
NO971557D0 (no) TIE-2-ligander, fremgangsmåte ved fremstilling samt anvendelse derav
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
Wong et al. Glutathione concentration in oral cancer tissues
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
JP2018512387A (ja) 聴力損傷予防用ペプチド及びそれを含む組成物
Baker Jr et al. Occupational lead exposure, nephropathy, and renal cancer
Camargo et al. Aggressive metastatic follicular thyroid carcinoma with anaplastic transformation arising from a long-standing goiter in a patient with Pendred's syndrome
EP1408333A3 (de) Diagnose und behandlung von alzheimer's krankheit
Hällgren et al. Cerebrospinal fluid ferritin in patients with cerebral infarction or bleeding
Pidala et al. Ixazomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium phase II trial
WO2002096468A3 (de) Methode zur diagnose und therapie des nierenzellkarzinoms
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2002040672A3 (en) Compositions and methods relating to breast specific genes and proteins
KR20210143866A (ko) Kdm5a 유전자 및 atrx 유전자의 용도
Merrin et al. Chemotherapy of advanced renal cell carcinoma with vinblastine and CCNU
Qazi et al. Estrogen receptors and the pattern of relapse in breast cancer
WO2002040673A3 (en) Compositions and methods relating to lung specific genes and proteins
DE3751646T2 (de) Rekombinantes Produkt
Suzuki et al. Molybdenum and copper kinetics after tetrathiomolybdate injection in LEC rats: specific role of serum albumin
JP2005511769A (ja) アポトーシスを誘導するフェチュインとポリペプチドの精製方法
WO1999037775A3 (en) Compositions and methods for detecting and treating breast cancer
AU2017235571B2 (en) Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002748562

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002748562

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10479200

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002748562

Country of ref document: EP